News Desk, Amar Ujala, Chandigarh
Updated Thu, 19 Nov 2020 05:46 PM IST
Listen to the news
Trial will start in Rohtak, Hyderabad and Goa
The third phase of the co-vaccine trial will start from PGIMS Rohtak, Hyderabad and Goa. Under this, 200-200 volunteers in three institutions will be given vaccine doses from Friday. This dose will be of six MGs. The second dose will be given 28 days after the first dose and the antibodies will be tested in their body after 48 days. On getting the right result, a total of 25,800 volunteers in 21 identified institutions across the country will be given this dose. This information was given by Dr. OP Kalra, Vice Chancellor of PGI on Wednesday. He said that the risk of co-vaccine is very low. In the research so far, two volunteers have had mild fever and pain in place of vaccine. All our volunteers are healthy and none have been reported to have corona yet.
Research will see what side effects the vaccine has and how long its effect lasts. Because it is not yet known how long the effect of the antibodies produced after the vaccine lasts. Antibodies will be tested inside volunteers for the next one year.
Vaccine can come in the market after February
The VC said that the vaccine may come in the market after February. Currently, the India biotech company is conducting research on this vaccine. If successful in research, ICMR will provide the vaccine to the company concerned for manufacture. After that the vaccine will be available in the market. He also informed that Union Health Minister Dr. Harsh Vardhan will inaugurate the modular OT on Friday.
I Will be administered trial dose of Coronavirus vaccine #Covaxin a Bharat Biotech product Tomorrow at 11 am at Civil Hospital, Ambala Cantt under the expert supervision of a team of Doctors from PGI Rohtak and Health Department. I have volunteered to take the trial dose.
– ANIL VIJ MINISTER HARYANA (@anilvijminister) November 19, 2020